Myositis Autoantibodies in Patients with Suspected Post-Treatment Lyme Disease Syndrome
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F23%3A73621444" target="_blank" >RIV/61989592:15110/23:73621444 - isvavai.cz</a>
Alternative codes found
RIV/00098892:_____/23:10157904
Result on the web
<a href="https://www.mdpi.com/2075-1729/13/2/527" target="_blank" >https://www.mdpi.com/2075-1729/13/2/527</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3390/life13020527" target="_blank" >10.3390/life13020527</a>
Alternative languages
Result language
angličtina
Original language name
Myositis Autoantibodies in Patients with Suspected Post-Treatment Lyme Disease Syndrome
Original language description
Most patients suffering from Lyme disease are effectively treated with antibiotics. Insome patients, however, problems persist for a long time despite appropriate therapy. The termpost-treatment Lyme disease syndrome (PTLDS) is currently used for this condition in scientificliterature. The pathogenesis is still not precisely known, but the involvement of immunopathologicalmechanisms is assumed. In our study, we analyzed the presence of autoantibodies including myositisspecific(MSA) and myositis-associated autoantibodies (MAA) in patients with laboratory provenhistory of Lyme disease and with clinical symptoms of PTLDS. A total of 59 patients meeting thecriteria for PTLDS were enrolled in this study. The control group consisted of 40 patients undergoingdifferential diagnosis of neurological disorders without clinical and/or laboratory-proven history ofLyme disease. The presence of autoantibodies was determined by immunoblot methods and positivesamples were further tested for serum creatine kinase (CK) and myoglobin levels. The presence ofmyositis autoantibodies was detected in 18 subjects with suspected PTLDS (30.5%), but only in 5%of control subjects exhibiting no evidence of Lyme disease history. The difference was statisticallysignificant (p = 0.002). The subsequent biochemical analysis of muscle-damage markers in positivesubjects found a mild elevation in six MSA/MAA-positive PTLDS patients. The study detected raisedMSA/MAA autoantibodies formation in the group of PTLDS patients raising the question abouttheir involvement in the pathogenesis of this syndrome.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30102 - Immunology
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Life
ISSN
2075-1729
e-ISSN
2075-1729
Volume of the periodical
13
Issue of the periodical within the volume
2
Country of publishing house
CH - SWITZERLAND
Number of pages
8
Pages from-to
527
UT code for WoS article
000940123400001
EID of the result in the Scopus database
2-s2.0-85148956065